The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
 
Jasmine Huynh
No Relationships to Disclose
 
Justin Chen
No Relationships to Disclose
 
Edward Jae-Hoon Kim
Consulting or Advisory Role - Celgene; Eisai; Lilly
Speakers' Bureau - Celgene; Eisai
Research Funding - Astellas Pharma (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dynavax Technologies (Inst); EpicentRx (Inst); ERYTECH Pharma (Inst); Eureka Therapeutics (Inst); Fibrogen (Inst); Halozyme (Inst); Merck (Inst); NGM BIOPHARMACEUTICALS (Inst); OncoMed (Inst); Samumed (Inst)
 
David R. Gandara
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boehringer Ingelheim; CellMax Life (Inst); Guardant Health (Inst); Inivata; IO Biotech (Inst); Lilly; Merck; OncoCyte (Inst); Pfizer; Roche/Genentech
Research Funding - AstraZeneca/MedImmune (Inst); Merck (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Thomas John Semrad
Consulting or Advisory Role - Celgene
 
Jonathan W. Riess
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Heron; Loxo; Medtronic; Spectrum Pharmaceuticals
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Merck (Inst); Novartis (Inst); Spectrum Pharmaceuticals (Inst)
 
Tianhong Li
Consulting or Advisory Role - Archer; Foundation Medicine; HERON
Research Funding - Eureka Therapeutics (Inst); Hengrui Therapeutics (Inst); Immunologic Therapeutics, Lt.D (Inst); Merck (Inst); Pfizer (Inst)
 
Chun-Yi Wu
No Relationships to Disclose
 
Chao Zhang
No Relationships to Disclose
 
Aiming Yu
No Relationships to Disclose
 
Karen Matsukuma
No Relationships to Disclose
 
Karen Kelly
Honoraria - Merck
Consulting or Advisory Role - Abbvie; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; EMD Serono; Genentech/Roche; Inivata; Merck; Novartis; Pfizer; Regeneron; Symphogen
Research Funding - Abbvie (Inst); Astellas Pharma; Bristol-Myers Squibb; EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Regeneron (Inst); Tizona Therapeutics, Inc.; Transgene
Patents, Royalties, Other Intellectual Property - Author Royalties for UpToDate, an evidence based, peer reviewed information resource, available via the web, desktop, and PDA.
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; EMD Serono; Genentech/Roche; Lilly; Merck; Merck; Regeneron